Shots:

• The P-II study evaluates VLA15 in 294 patients aged ≥5yr. with LD. The pediatric results are expected in H1’22
• In the sub-analysis of patients aged 18-65yrs., the therapy was found to be immunogenic after administration of 2 or 3 primary series doses & strong immune responses were observed  & induction of anti-OspA IgG Ab titers was higher in patients with three-dose primary series compared to two-dose primary series. The results were consistent with previous studies of VLA15 & no vaccine-related SAEs were identified
• Based on P-II results, the companies are planning to advance in the P-III trial with a three-dose primary series vaccination schedule & is expected to be initiated in Q3'22

Ref: Pfizer | Image: Pfizer